Contact Us
800-658-2849

Vaccines Redefined

This block contains code to allow dead links in the navigation to function properly. This block will not be visible on the live site.

DO NOT DELETE

About Us 

The Company’s corporate partnering strategy is to out-license our proprietary alphavaccine technology for specific disease and/or antigen applications for commercialization. 

AlphaVax is developing both anti-infective and anti-cancer vaccines incorporating a new vaccine technology -- so as to redefine vaccines and their rôle in medicine 

Technology

The alphavaccine technology is based on AlphaVax’s proprietary replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus.  

Products

AlphaVax 's in-house focus is today on  the commercial potential of its alphavaccine vector technology in cancer immunotherapy.​ External third party partners are working on anti-infective vaccines.

AlphaVax, Inc. (AVX)

We are a privately-held, clinical-stage biopharmaceutical company, that has used its proprietary alphavaccine vector platform technology to generate a portfolio of seven vaccine candidates for infectious disease prevention and cancer immunotherapy. Additional candidates for bio-defence applications have also been developed.

Four alphavaccine candidates, targeting human cytomegalovirus, influenza A virus, prostate cancer and HIV-1, have been evaluated in five Phase 1 clinical trials. More recently, AVX has focused its efforts in an additional three clinical trials with two additional vaccine candidates (one in breast cancer, two in GI cancers) in the development of immunotherapeutic vaccines for the treatment of various cancers. From these latter efforts, AVX has successfully progressed the development of its proprietary alphavaccine technology, to create new, potentially first-in-class, vaccines that engage the patient’s immune system  both to recognize and fight off various cancers. 

Results from AVX’s first trial evaluating its CEA alphavaccine in patients with Stage IV colon cancer showed the vector technology was able to “break self-tolerance” and a trend for enhanced survival in patients with CEA-specific T cell responses. 

As a follow-up, AVX has completed clinical trials in breast cancer and gastrointestinal cancers (in Stage III patients). 

Selected Recent Accomplishments


  • Patient accrual in the AVX 701 study of Stage III GI cancers concluded in early summer 2016.
  • The USDA (in 1Q 2016) approved the production platform incorporating our technology that permits the manufacture of herd-specific custom vaccines.
  • Our licensee for selected veterinary vaccines was  acquired by Merck Animal Health in late 2015..
  • Presentation at November 2015's SITC meeting of a study indicating a trend for longer survival in Stage IV CEA cancer patients.  
  • Patient accrual in the second cohort in the AVX 901 study of a HER2-VRP vaccine clinical trial was completed in the third quarter of 2015. 
  • Executed an exclusive license with the US Department of Defense (DoD), Office of Chemical-Biological Medical Systems (CBMS) to the alphavaccine platform for the development of certain vaccines.